CBS 2019
CBSMD教育中心
English

推荐文献

科研文章

荐读文献

Development and validation of a simple risk score to predict 30-day readmission after percutaneous coronary intervention in a cohort of medicare patients 稳定性冠心病诊断与治疗指南 Mode of Death in Heart Failure With Preserved Ejection Fraction Derivation and Validation of a Chronic Total Coronary Occlusion Intervention Procedural Success Score From the 20,000-Patient EuroCTO Registry：The EuroCTO (CASTLE) Score When high‐volume PCI operators in high‐volume hospitals move to lower volume hospitals—Do they still maintain high volume and quality of outcomes? Association between urinary dickkopf-3, acute kidney injury, and subsequent loss of kidney function in patients undergoing cardiac surgery: an observational cohort study Generalizing Intensive Blood Pressure Treatment to Adults With Diabetes Mellitus Advances in Coronary No-Reflow Phenomenon-a Contemporary Review A Randomized Trial to Assess Regional Left Ventricular Function After Stent Implantation in Chronic Total Occlusion The REVASC Trial Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial
|<<... 14 15 16 17 18 19 20 ...>>|

Recommandation StatementVolume 75, Issue 18, May 2020

JOURNAL：JACC Article Link

Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From the ACC’s Interventional Council and SCAI

GP Frederick, AJ Kirtane and American College of Cardiology’s Interventional Council and the Society for Cardiovascular Angiography and Interventions. Keywords: catheterization laboratory; coronavirus; NSTEMI; STEMI

Full Text PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top